All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results

Amar H Kelkar1, Shai Shimony2, Edward R Scheffer Cliff3

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA; Harvard T H Chan School of Public Health, Boston, MA, USA.

The Lancet. Haematology
|August 31, 2023
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos